Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

ClinicalTrials.gov ID: NCT01633112

Public ClinicalTrials.gov record NCT01633112. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 11:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

Study identification

NCT ID
NCT01633112
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
1,064 participants

Conditions and interventions

Interventions

  • fingolimod Drug
  • glatiramer acetate Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 8, 2012
Primary completion
Apr 29, 2018
Completion
Apr 29, 2018
Last update posted
May 27, 2019

2012 – 2018

United States locations

U.S. sites
101
U.S. states
36
U.S. cities
91
Facility City State ZIP Site status
Novartis Investigative Site Cullman Alabama 35058
Novartis Investigative Site Phoenix Arizona 85004
Novartis Investigative Site Phoenix Arizona 85013
Novartis Investigative Site Phoenix Arizona 85018
Novartis Investigative Site Tucson Arizona 85741
Novartis Investigative Site Los Angeles California 90089
Novartis Investigative Site Sacramento California 95817
Novartis Investigative Site Aurora Colorado 80045
Novartis Investigative Site Boulder Colorado 80304
Novartis Investigative Site Denver Colorado 80220
Novartis Investigative Site Fort Collins Colorado 80528
Novartis Investigative Site Loveland Colorado 80538
Novartis Investigative Site Fairfield Connecticut 06824
Novartis Investigative Site Newark Delaware 19713
Novartis Investigative Site Washington D.C. District of Columbia 20007
Novartis Investigative Site Jacksonville Florida 32209
Novartis Investigative Site Maitland Florida 32751
Novartis Investigative Site Naples Florida 34119
Novartis Investigative Site New Port Richey Florida 34653
Novartis Investigative Site Orlando Florida 32806
Novartis Investigative Site Ormond Beach Florida 32174
Novartis Investigative Site Pompano Beach Florida 33060
Novartis Investigative Site Ponte Vedra Beach Florida 32082-4627
Novartis Investigative Site Port Charlotte Florida 33952
Novartis Investigative Site Sarasota Florida 34243
Novartis Investigative Site Tallahassee Florida 32308
Novartis Investigative Site Tampa Florida 33609
Novartis Investigative Site Vero Beach Florida 32960
Novartis Investigative Site West Palm Beach Florida 33407
Novartis Investigative Site Atlanta Georgia 30327
Novartis Investigative Site Elk Grove Village Illinois 60007
Novartis Investigative Site Evanston Illinois 60201
Novartis Investigative Site Flossmoor Illinois 60422
Novartis Investigative Site Northbrook Illinois 60062
Novartis Investigative Site Indianapolis Indiana 46202
Novartis Investigative Site Indianapolis Indiana 46256
Novartis Investigative Site West Des Moines Iowa 50314
Novartis Investigative Site Kansas City Kansas 66160
Novartis Investigative Site Lenexa Kansas 66212
Novartis Investigative Site Louisville Kentucky 40207
Novartis Investigative Site Hammond Louisiana 70403
Novartis Investigative Site New Orleans Louisiana 70121
Novartis Investigative Site Baltimore Maryland 21201
Novartis Investigative Site Boston Massachusetts 02215
Novartis Investigative Site Springfield Massachusetts 01104
Novartis Investigative Site Detroit Michigan 48201
Novartis Investigative Site Detroit Michigan 48202
Novartis Investigative Site Farmington Hills Michigan 48334
Novartis Investigative Site Grand Rapids Michigan 49503
Novartis Investigative Site Traverse City Michigan 49684-2340
Novartis Investigative Site Kansas City Missouri 64111
Novartis Investigative Site St Louis Missouri 63104
Novartis Investigative Site St Louis Missouri 63131
Novartis Investigative Site St Louis Missouri 63141
Novartis Investigative Site Great Falls Montana 59405
Novartis Investigative Site Las Vegas Nevada 89106
Novartis Investigative Site Freehold New Jersey 07728
Novartis Investigative Site Newark New Jersey 07103
Novartis Investigative Site Teaneck New Jersey 07666
Novartis Investigative Site Albuquerque New Mexico 87131
Novartis Investigative Site Albany New York 12208
Novartis Investigative Site Amherst New York 14226
Novartis Investigative Site Buffalo New York 14203
Novartis Investigative Site Patchogue New York 11772
Novartis Investigative Site Rochester New York 14642
Novartis Investigative Site Stony Brook New York 11794
Novartis Investigative Site Syracuse New York 13210
Novartis Investigative Site Chapel Hill North Carolina 27599-9500
Novartis Investigative Site Charlotte North Carolina 28204
Novartis Investigative Site Winston-Salem North Carolina 27157
Novartis Investigative Site Akron Ohio 44320
Novartis Investigative Site Bellevue Ohio 44811
Novartis Investigative Site Columbus Ohio 43210
Novartis Investigative Site Columbus Ohio 43221
Novartis Investigative Site Dayton Ohio 45408
Novartis Investigative Site Toledo Ohio 43614
Novartis Investigative Site Oklahoma City Oklahoma 73104
Novartis Investigative Site Oklahoma City Oklahoma 73112
Novartis Investigative Site Tulsa Oklahoma 74137
Novartis Investigative Site Portland Oregon 97225
Novartis Investigative Site Philadelphia Pennsylvania 19141
Novartis Investigative Site Spartanburg South Carolina 29302
Novartis Investigative Site Cordova Tennessee 38018
Novartis Investigative Site Knoxville Tennessee 37934
Novartis Investigative Site Nashville Tennessee 37204
Novartis Investigative Site Nashville Tennessee 37205
Novartis Investigative Site Dallas Texas 75214
Novartis Investigative Site Houston Texas 77030
Novartis Investigative Site Round Rock Texas 78681
Novartis Investigative Site San Antonio Texas 78258
Novartis Investigative Site Sherman Texas 75092
Novartis Investigative Site Salt Lake City Utah 84103
Novartis Investigative Site Alexandria Virginia 22310
Novartis Investigative Site Charlottesville Virginia 22903
Novartis Investigative Site Norfolk Virginia 23507
Novartis Investigative Site Richmond Virginia 23226
Novartis Investigative Site Roanoke Virginia 24018
Novartis Investigative Site Issaquah Washington 98029
Novartis Investigative Site Seattle Washington 98101
Novartis Investigative Site Seattle Washington 98122-4379
Novartis Investigative Site Milwaukee Wisconsin 53215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01633112, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 27, 2019 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01633112 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →